Prognosis of Behavioral Addiction in Parkinson's Disease (PROBA-PD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02671240|
Recruitment Status : Recruiting
First Posted : February 2, 2016
Last Update Posted : May 22, 2017
Our hypothesis is that the conventional treatment of Behavioral Addiction in Parkinson's disease is often not effective, and that affects the motor aspects (worsening akinéto-rigid syndrome and / or worsening of dyskinesia due to higher levodopa doses to compensate for the drop in behavioral addictions) and non-motor (withdrawal syndrome dopamine agonist) anxiously including apathy.
Our goal is to describe the natural history of Behavioral Addiction under the effect of the evolution of the disease and adapt treatment according to the prior art, through a study of a larger population of patients than in the few published studies.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Actual Study Start Date :||October 24, 2016|
|Estimated Primary Completion Date :||October 24, 2021|
|Estimated Study Completion Date :||October 24, 2021|
|- Patients with behavioral addiction|
|- Patients with no behavioral addiction|
- Survival time before disappearance of behavioral addiction defined by a score of less than 2 on the scale of behavioral assessment of Parkinson's disease [ Time Frame: 12 months after selection ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02671240
|Contact: Mathieu ANHEIM, MD, PhD||33 (0)3 88 12 85 firstname.lastname@example.org|
|Service de Neurologie||Recruiting|
|Strasbourg, France, 67098|
|Contact: Mathieu ANHEIM, MD, PhD 03 88 12 85 32 email@example.com|
|Study Director:||Mathieu ANHEIM, MD, PhD||University Hospital, Strasbourg, France|